THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy GoodRx (Nasdaq: GDRX), the leading platform for medication ...
The other half received the same aggressive cholesterol-lowering treatment, but their injections contained Repatha. After 48 weeks, their LDL cholesterol had dropped to unprecedented low levels (the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results